Solvias

Nitrosamines, a group of chemical compounds known for their carcinogenic properties, have become a major focus for regulators worldwide. For pharmaceutical companies, the stakes couldn’t be higher: 🚫 The presence of nitrosamines can lead to costly recalls, damaging both finances and reputation. 🚫 Insufficient data on nitrosamines can result in approval delays, adding time and expense to the development process. Proactively managing nitrosamine risks is essential for compliance, safety, and maintaining public trust. Solvias is here to help with resources to support your efforts: 🔗 White Paper: The High-Stakes Nature of Nitrosamine Impurities in APIs https://lnkd.in/eJfZ9eHc 🔗 Flyer: New FDA Nitrosamine Impurities Guide - What Drug Developers Need to Know https://lnkd.in/evGKnrHF 🔗 Flyer: The Risk of Nitrosamine Impurities in Biologics - What Biopharma Developers Need to Know https://lnkd.in/eTDDvfyN Download these valuable resources today and stay ahead in your nitrosamine control strategy. #Nitrosamines #NDSRI

Antibody-Drug Conjugates (ADCs) represent a unique blend of small molecule chemistry and biologics—and navigating their complexities requires a partner with expertise in both. In this video, Christoph Lederer, Head Operations Separation & ELISA, shares how Solvias supports ADC developers at every step, from preclinical to commercial stages. With capabilities to handle both the small molecule and biologic components of ADCs, we provide comprehensive solutions to help bring your innovation to its destination. 🔗 Download our white paper to learn more: https://lnkd.in/e4DJ__BT #AntibodyDrugConjugates #ADCs #CancerResearch #Oncology

In September 2024, the FDA released its much-anticipated Control of Nitrosamine Impurities in Human Drugs guidance — the second major update since the original 2020 release and the first revision in 2021. What does this mean for drug developers? Swipe through our carousel to uncover the key updates. 📄 Want to dive deeper? Download our flyer: https://lnkd.in/e8R38Jpd 💡 Stay informed. Stay ahead. #Nitrosamines #NDSRI

We’re proud to announce that Yannick Baschung, Head of Drug Delivery and Physical Characterization Services at Solvias, has been featured in the Drug Delivery to the Lungs Supplement 2024, published by Pharmaceutical Manufacturing and Packing Sourcer (PMPS)! 📄 In his interview (pages 20–23), Yannick explores cutting-edge advancements and critical challenges shaping the future of respiratory drug delivery. 🔗 Read the full publication here: https://lnkd.in/eTzew6QR Thank you Samedan Ltd for this opportunity! #OINDP #DrugDelivery #RespiratoryHealth #PharmaInnovation #Solvias #PMPS

Antibody-Drug Conjugates (ADCs) are groundbreaking therapies, but their payloads present unique challenges in testing. These payloads, or warheads, are multiple orders of magnitude more potent than conventional chemotherapeutic, making their handling and testing both critical and complex. Hear from Christoph Lederer, Head of Operations Separation & ELISA, as he discusses how Solvias is addressing this challenge with our new state-of-the-art toxicology lab, equipped to handle products with Occupational Exposure Limit (OELs) as low as 5 ng/m³! Curious to learn more? Access our latest white paper for a comprehensive look at the strategies needed to tackle ADC challenges and bring your innovation to its destination. 🔗 Download it now: https://lnkd.in/eyGKbr5F #AntibodyDrugConjugates #ADCs #CancerResearch #Oncology

We're excited to share a new testimonial from Barbara Tevelev, Manager Regulatory CMC Biologics at Pfizer highlighting how Solvias's Targeted Locus Amplification (TLA) technology has been instrumental in advancing their CLD development strategy. Learn more about how Solvias is helping companies like Pfizer achieve breakthrough clarity in cell line development. Download a full clonality case study and understand how we can help bring your innovation to its destination: 🔗 https://lnkd.in/eaGFWyrF #CustomerTestimonial #CellLineDevelopment #TLAtechnology #celltherapies #genetherapies #cgt #atmp #GenotypicCharacterization

This Thanksgiving, we express our gratitude for our dedicated team, valued clients, and the remarkable achievements we accomplish together. Wishing you all a Thanksgiving filled with joy, warmth, and happiness! #HappyThanksgiving

Last week, we asked you to guess the Grand Opening date of our brand-new Center of Excellence in Research Triangle Park, NC, and now it’s time to reveal the answer: January 22nd, 2025! 🗓️ Join us in celebrating this milestone! RSVP today and secure your spot at the Grand Opening: https://lnkd.in/ehMKTwZJ See you there! #CGT #CellTherapy #GeneTherapy #RTP

In May 2024, we proudly announced the expansion of our global network with a brand-new Center of Excellence in Research Triangle Park, NC. This state-of-the-art facility will be dedicated to biologics and cell & gene therapy testing. The countdown to the Grand Opening has begun — we already have the date locked in! Do you know when it is? Cast your vote below! #CGT #celltherapy #genetherapy #RTP

Antibody-Drug Conjugates (ADCs) are transforming cancer therapy by pairing precision targeting with potent cytotoxic effects. But developing these complex molecules is no simple task. Join Christoph Lederer, Head of Operations Separation & ELISA at Solvias, as he shares insights into the analytical hurdles of ADC development — from merging expertise in both small molecules and biologics to maintaining linker stability and achieving an optimal drug-to-antibody ratio (DAR). Ready to dive deeper? Access our latest white paper for a comprehensive look at the strategies needed to tackle ADC challenges and bring your innovation to its destination. 🔗 Download it now: https://lnkd.in/eTiBYqa9 #AntibodyDrugConjugates #ADCs #CancerResearch #Oncology